866-997-4948(US-Canada Toll Free)

Endometriosis-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 131 Pages

Endometriosis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis-Pipeline Review, H2 2017, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 9, 7, 1, 14, 5 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Endometriosis-Overview 8
Endometriosis-Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Endometriosis-Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Endometriosis-Companies Involved in Therapeutics Development 28
AbbVie Inc 28
Addex Therapeutics Ltd 28
APAvadis Biotechnologies Srl 29
Astellas Pharma Inc 29
Bayer AG 30
ElexoPharm GmbH 30
EndoCeutics Inc 31
Enteris BioPharma Inc 31
Evotec AG 32
Forendo Pharma Ltd 32
Kissei Pharmaceutical Co Ltd 33
Lipicard Technologies Ltd 33
Luye Pharma Group Ltd 33
Nippon Shinyaku Co Ltd 34
Ogeda SA 34
Philogen SpA 35
Repros Therapeutics Inc 35
SK Chemicals Co Ltd 35
Takeda Pharmaceutical Co Ltd 36
ValiRx Plc 36
Viramal Ltd 37
Endometriosis-Drug Profiles 38
acolbifene hydrochloride + GnRH Agonist + prasterone-Drug Profile 38
ADX-68692-Drug Profile 39
BAY-1128688-Drug Profile 40
BAY-1158061-Drug Profile 41
BAY-1817080-Drug Profile 42
BAY-1834845-Drug Profile 43
danazol-Drug Profile 44
Drug 1 for Endometriosis-Drug Profile 45
Drug 2 for Endometriosis-Drug Profile 46
Drug 3 for Endometriosis-Drug Profile 47
Drug 4 for Endometriosis-Drug Profile 48
Drug for Endometriosis-Drug Profile 49
Drug to Antagonize P2X3 for Endometriosis-Drug Profile 50
Drug to Inhibit C-Jun for Endometriosis-Drug Profile 51
Drugs for Endometriosis and Uterine Fibroids-Drug Profile 52
EC-313-Drug Profile 53
elagolix sodium-Drug Profile 54
fezolinetant-Drug Profile 60
FP-5677-Drug Profile 63
goserelin ER-Drug Profile 64
KLH-2109-Drug Profile 65
leuprolide acetate-Drug Profile 67
LT-6121-Drug Profile 68
MIA-602-Drug Profile 69
NHP-07-Drug Profile 70
NS-580-Drug Profile 71
opigolix-Drug Profile 72
Peptides for Endometriosis and Hepatic Tumor-Drug Profile 73
Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor-Drug Profile 74
PGL-2001-Drug Profile 75
progesterone-Drug Profile 76
Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome-Drug Profile 77
relugolix-Drug Profile 78
SKI-2670-Drug Profile 84
Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health-Drug Profile 85
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Oncology and Uterine Fibroids-Drug Profile 86
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis-Drug Profile 87
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis-Drug Profile 88
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers-Drug Profile 89
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis-Drug Profile 90
Small Molecules to Inhibit HSD17B1 for Endometriosis-Drug Profile 91
SR-16234-Drug Profile 92
Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy-Drug Profile 93
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile 94
telapristone acetate-Drug Profile 95
tetravil-Drug Profile 104
TOT-206-Drug Profile 106
triptorelin acetate ER-Drug Profile 107
VAL-301-Drug Profile 108
vilaprisan-Drug Profile 109
VPE-001-Drug Profile 111
Endometriosis-Dormant Projects 112
Endometriosis-Discontinued Products 114
Endometriosis-Product Development Milestones 115
Featured News & Press Releases 115
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List of Tables
Number of Products under Development for Endometriosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Endometriosis-Pipeline by AbbVie Inc, H2 2017
Endometriosis-Pipeline by Addex Therapeutics Ltd, H2 2017
Endometriosis-Pipeline by APAvadis Biotechnologies Srl, H2 2017
Endometriosis-Pipeline by Astellas Pharma Inc, H2 2017
Endometriosis-Pipeline by Bayer AG, H2 2017
Endometriosis-Pipeline by ElexoPharm GmbH, H2 2017
Endometriosis-Pipeline by EndoCeutics Inc, H2 2017
Endometriosis-Pipeline by Enteris BioPharma Inc, H2 2017
Endometriosis-Pipeline by Evotec AG, H2 2017
Endometriosis-Pipeline by Forendo Pharma Ltd, H2 2017
Endometriosis-Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Endometriosis-Pipeline by Lipicard Technologies Ltd, H2 2017
Endometriosis-Pipeline by Luye Pharma Group Ltd, H2 2017
Endometriosis-Pipeline by Nippon Shinyaku Co Ltd, H2 2017
Endometriosis-Pipeline by Ogeda SA, H2 2017
Endometriosis-Pipeline by Philogen SpA, H2 2017
Endometriosis-Pipeline by Repros Therapeutics Inc, H2 2017
Endometriosis-Pipeline by SK Chemicals Co Ltd, H2 2017
Endometriosis-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Endometriosis-Pipeline by ValiRx Plc, H2 2017
Endometriosis-Pipeline by Viramal Ltd, H2 2017
Endometriosis-Dormant Projects, H2 2017
Endometriosis-Dormant Projects, H2 2017 (Contd..1), H2 2017
Endometriosis-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Endometriosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *